Emil Nasyrov
Research Subjects
Emil Nasyrov has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Bogomil Voykov
Centre for Ophthalmology, University Hospital Tuebingen, Tuebingen, Germany
4 shared publications- Bogomil Voykov
Universitäts-Augenklinik Tübingen
4 shared publications - David Adrian Merle
Institute of Ophthalmology, University College London, 11-43 Bath Street, London, England, EC1V 9EL, United Kingdom, 44 020 7608 6800
3 shared publications - Lasse Wolfram
Department for Ophthalmology, University Eye Clinic, Eberhard Karls University of Tübingen, Tübingen, Germany
3 shared publications Caroline J. Gassel
Centre for Ophthalmology, University Hospital Tuebingen, Tuebingen, Germany
2 shared publicationsCaroline J. Wenzel
Centre for Ophthalmology, University Hospital Tuebingen, Tuebingen, Germany
2 shared publications
Latest Publications
- Open Access
- 16 November 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Outcomes of Carlevale-type scleral-fixated intraocular lenses as a stable platform in silicone oil-filled eyes: a multicenter study
To evaluate functional, refractive, and morphological outcomes, and silicone oil (SiO)-related complications of Carlevale-type scleral-fixated intraocular lens (C-IOL) implantation with SiO tamponade. This multicenter case series included nine eyes that underwent C-IOL implantation combined with SiO tamponade, either simultaneously during primary retinal detachment surgery (56%), or sequentially, with the C-IOL already in place before retinal detachment repair and SiO tamponade (44%), across three centers. SiO tamponade consisted of standard 5000 cSt silicone oil (78%) or heavy fluorinated silicone oil (Densiron 68, 22%). Best-corrected visual acuity (BCVA), spherical equivalent (SE), intraocular pressure (IOP), SiO position, C-IOL stability, and adverse events were recorded preoperatively and at follow-up. Median age was 75.0 years (IQR 67.0–79.0); 67% were male. Median follow-up was 36.7 weeks (IQR 25.4–55.0). BCVA improved from 2.3 logMAR (IQR 1.3–2.3) preoperatively to 0.9 logMAR (IQR 0.9–1.8) at last follow-up (median ΔBCVA − 0.6) in 67% of eyes. Median SE remained near emmetropia, though with individual variability and available in only 6/9 eyes at ≥ 36 weeks. No IOP measurement exceeded 21 mmHg. Anatomical success was achieved in 78% of eyes. No clinically documented C-IOL decentration, tilt, or dislocation occurred. SiO was explanted in 33% of eyes at a median of 25.4 weeks (IQR 16.7–31.1); the remaining eyes retained tamponade through last follow-up. C-IOL opacification occurred in 22% (one explantation). Anterior SiO migration occurred in 44%, mostly limited to a small, clinically non-significant bubble; diffuse migration occurred in one eye only after explantation. Anterior-chamber irrigation was required in 22%. The combined surgical management of vitreoretinal surgery, SiO tamponade, and C-IOL fixation was associated with visual improvement, high anatomical success, and no clinically documented C-IOL decentration, tilt, or dislocation, although C-IOL opacification and anterior SiO migration warrant further prospective, comparative evaluation.
- 16 November 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessOutcomes of Carlevale-type scleral-fixated intraocular lenses as a stable platform in silicone oil-filled eyes: a multicenter study
To evaluate functional, refractive, and morphological outcomes, and silicone oil (SiO)-related complications of Carlevale-type scleral-fixated intraocular lens (C-IOL) implantation with SiO tamponade. This multicenter case series included nine eyes that underwent C-IOL implantation combined with SiO tamponade, either simultaneously during primary retinal detachment surgery (56%), or sequentially, with the C-IOL already in place before retinal detachment repair and SiO tamponade (44%), across three centers. SiO tamponade consisted of standard 5000 cSt silicone oil (78%) or heavy fluorinated silicone oil (Densiron 68, 22%). Best-corrected visual acuity (BCVA), spherical equivalent (SE), intraocular pressure (IOP), SiO position, C-IOL stability, and adverse events were recorded preoperatively and at follow-up. Median age was 75.0 years (IQR 67.0–79.0); 67% were male. Median follow-up was 36.7 weeks (IQR 25.4–55.0). BCVA improved from 2.3 logMAR (IQR 1.3–2.3) preoperatively to 0.9 logMAR (IQR 0.9–1.8) at last follow-up (median ΔBCVA − 0.6) in 67% of eyes. Median SE remained near emmetropia, though with individual variability and available in only 6/9 eyes at ≥ 36 weeks. No IOP measurement exceeded 21 mmHg. Anatomical success was achieved in 78% of eyes. No clinically documented C-IOL decentration, tilt, or dislocation occurred. SiO was explanted in 33% of eyes at a median of 25.4 weeks (IQR 16.7–31.1); the remaining eyes retained tamponade through last follow-up. C-IOL opacification occurred in 22% (one explantation). Anterior SiO migration occurred in 44%, mostly limited to a small, clinically non-significant bubble; diffuse migration occurred in one eye only after explantation. Anterior-chamber irrigation was required in 22%. The combined surgical management of vitreoretinal surgery, SiO tamponade, and C-IOL fixation was associated with visual improvement, high anatomical success, and no clinically documented C-IOL decentration, tilt, or dislocation, although C-IOL opacification and anterior SiO migration warrant further prospective, comparative evaluation.
- Open Access
- 21 August 2026
- Published by Springer Nature in BMC Ophthalmology
- Vol. 26 (1) , 518
Achieving low intraocular pressure in normal-tension glaucoma with the Preserflo MicroShunt: comparison with primary open-angle glaucoma and the XEN-45 Gel Stent
Background: Achieving low intraocular pressure (IOP) while minimizing surgical risk remains a central challenge in the management of normal-tension glaucoma (NTG). This study aimed to evaluate the efficacy and safety of the Preserflo MicroShunt (PMS) in NTG compared with primary open-angle glaucoma (POAG) and the XEN-45 Gel Stent. Methods: In this retrospective dual-comparison study, the primary outcomes were 2-year complete success (≥ 30% reduction in IOP from baseline and ≤ 12 mmHg without medication) and hazard ratios (HRs) for surgical failure. Kaplan–Meier analyses and univariate Cox models were used to compare NTG PMS and POAG PMS patients (1:1 matched cohort; PMS analysis) and exploratory multivariable models for consecutive NTG PMS and NTG XEN-45 patients (NTG analysis). Secondary outcomes included bleb revision and complication rates. Results: In the PMS analysis, 50 NTG patients were matched to 50 POAG patients. Two-year success rates were 69% and 45%, respectively ( p = 0.0277). NTG diagnosis was associated with a lower risk of failure (HR 0.48, 95% CI 0.24–0.96) and fewer bleb revisions. In the NTG analysis, 45 PMS patients were compared with 23 XEN-45 patients. Two-year success rates were 71% and 17%, respectively ( p < 0.0001). PMS implantation was associated with a lower risk of failure (HR 0.25, 95% CI 0.12–0.53) and fewer needling procedures. No sight-threatening complications occurred in any group. Conclusions: PMS implantation enabled a high rate of sustained low IOP control, with significantly higher success rates than in matched POAG patients and NTG XEN-45 patients, while requiring fewer postoperative interventions. These findings indicate that the PMS might achieve lower IOP thresholds in NTG than previously expected requiring evaluation in larger prospective studies.
- 21 August 2026
- Published by Springer Nature in BMC Ophthalmology
- Vol. 26 (1) , 518
Open AccessAchieving low intraocular pressure in normal-tension glaucoma with the Preserflo MicroShunt: comparison with primary open-angle glaucoma and the XEN-45 Gel Stent
Background: Achieving low intraocular pressure (IOP) while minimizing surgical risk remains a central challenge in the management of normal-tension glaucoma (NTG). This study aimed to evaluate the efficacy and safety of the Preserflo MicroShunt (PMS) in NTG compared with primary open-angle glaucoma (POAG) and the XEN-45 Gel Stent. Methods: In this retrospective dual-comparison study, the primary outcomes were 2-year complete success (≥ 30% reduction in IOP from baseline and ≤ 12 mmHg without medication) and hazard ratios (HRs) for surgical failure. Kaplan–Meier analyses and univariate Cox models were used to compare NTG PMS and POAG PMS patients (1:1 matched cohort; PMS analysis) and exploratory multivariable models for consecutive NTG PMS and NTG XEN-45 patients (NTG analysis). Secondary outcomes included bleb revision and complication rates. Results: In the PMS analysis, 50 NTG patients were matched to 50 POAG patients. Two-year success rates were 69% and 45%, respectively ( p = 0.0277). NTG diagnosis was associated with a lower risk of failure (HR 0.48, 95% CI 0.24–0.96) and fewer bleb revisions. In the NTG analysis, 45 PMS patients were compared with 23 XEN-45 patients. Two-year success rates were 71% and 17%, respectively ( p < 0.0001). PMS implantation was associated with a lower risk of failure (HR 0.25, 95% CI 0.12–0.53) and fewer needling procedures. No sight-threatening complications occurred in any group. Conclusions: PMS implantation enabled a high rate of sustained low IOP control, with significantly higher success rates than in matched POAG patients and NTG XEN-45 patients, while requiring fewer postoperative interventions. These findings indicate that the PMS might achieve lower IOP thresholds in NTG than previously expected requiring evaluation in larger prospective studies.
- Open Access
- 15 August 2026
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- p. 1-10
Preserflo microshunt outcomes in pigmentary glaucoma: a propensity score–matched comparison with primary open-angle glaucoma
Purpose: To evaluate the outcomes of Preserflo MicroShunt (PMS) implantation in pigmentary glaucoma (PG) and compare them with a matched primary open-angle glaucoma (POAG) cohort. Patients and methods: This retrospective study included consecutive patients with PG undergoing PMS implantation between 2021 and 2025 at a single tertiary centre. A 1:2 propensity score–matched POAG control group was created based on demographic and clinical baseline characteristics. The primary outcome was surgical success at 2 years, defined as ≥ 20% IOP reduction and IOP ≤ 18 mmHg without hypotony-related complications. Secondary outcomes included stricter success criteria, IOP reduction, medication use, revisions, and complications. Results: Thirty-one PG patients were matched to 62 POAG patients. Median follow-up was 28 and 32 months, respectively. PMS implantation resulted in significant and sustained IOP reduction in both groups (all p < 0.01), with no significant differences between PG and POAG at any time point. Median IOP at 2 years was 14 mmHg in both groups. IOP-lowering agents decreased to a median of 0 in both groups, with most patients remaining medication-free. Complete success at 2 years was 61% in PG and 49% in POAG ( p = 0.35). Bleb revisions were required in 45% and 52%. Outcomes across stricter success criteria and complications were not significantly different. Conclusions: PMS implantation in PG was not associated with significantly different efficacy, safety and revision burden compared with POAG. The distinct pathophysiology of PG does not appear to adversely affect surgical outcomes, supporting the PMS as a viable treatment option in this population.
- 15 August 2026
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- p. 1-10
Open AccessPreserflo microshunt outcomes in pigmentary glaucoma: a propensity score–matched comparison with primary open-angle glaucoma
Purpose: To evaluate the outcomes of Preserflo MicroShunt (PMS) implantation in pigmentary glaucoma (PG) and compare them with a matched primary open-angle glaucoma (POAG) cohort. Patients and methods: This retrospective study included consecutive patients with PG undergoing PMS implantation between 2021 and 2025 at a single tertiary centre. A 1:2 propensity score–matched POAG control group was created based on demographic and clinical baseline characteristics. The primary outcome was surgical success at 2 years, defined as ≥ 20% IOP reduction and IOP ≤ 18 mmHg without hypotony-related complications. Secondary outcomes included stricter success criteria, IOP reduction, medication use, revisions, and complications. Results: Thirty-one PG patients were matched to 62 POAG patients. Median follow-up was 28 and 32 months, respectively. PMS implantation resulted in significant and sustained IOP reduction in both groups (all p < 0.01), with no significant differences between PG and POAG at any time point. Median IOP at 2 years was 14 mmHg in both groups. IOP-lowering agents decreased to a median of 0 in both groups, with most patients remaining medication-free. Complete success at 2 years was 61% in PG and 49% in POAG ( p = 0.35). Bleb revisions were required in 45% and 52%. Outcomes across stricter success criteria and complications were not significantly different. Conclusions: PMS implantation in PG was not associated with significantly different efficacy, safety and revision burden compared with POAG. The distinct pathophysiology of PG does not appear to adversely affect surgical outcomes, supporting the PMS as a viable treatment option in this population.
- Open Access
- 1 August 2026
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 20, 1-17
Preserflo MicroShunt Outcomes in Rare and Refractory Glaucoma Entities Compared with Matched Primary Open-Angle Glaucoma Controls: A Retrospective Exploratory Study
Purpose: To investigate the efficacy and safety of the Preserflo MicroShunt (PMS) in rare and refractory glaucoma entities (RRG) in comparison with primary open-angle glaucoma (POAG). Patients and Methods: In this retrospective exploratory study, the primary outcome was the complete 1-year success rate (≥ 20% reduction in IOP from baseline and ≤ 18 mmHg with no medication use). Kaplan–Meier estimates were compared between RRG and POAG (matched 1:1) using the log-rank test. Exploratory sub-analyses were performed for each RRG subgroup. The secondary outcomes included bleb revision and complication rates. Results: Eighty eyes were included in the RRG group (8 primary congenital (PCG), 11 juvenile open-angle (JOAG), 10 aphakic (AG), 14 combined mechanisms (CMG), 17 neovascular (NVG), 13 post-traumatic (TG), 4 oil-induced, 2 steroid-induced glaucoma, and 1 with idiopathically elevated episcleral venous pressure) and matched to 80 eyes with POAG based on baseline characteristics. The 1-year success rates were 56% in the RRG and 71% in the POAG groups (p = 0.0079). Exploratory subgroup analyses revealed significantly lower success in PCG (2/8), TG (8/13) and NVG (8/17). Success rates in the other groups were not significantly different from POAG. Bleb revisions were required significantly more frequently in the RRG group (58% vs 41%). Severe complications were observed in the RRG group, but did not reach significance. Conclusions: While the PMS demonstrated lower efficacy in RRG compared to POAG overall, this difference was primarily attributable to worse outcomes in NVG, TG, and PCG. Success rates in AG, JOAG, and CMG were not significantly different from POAG controls. The frequent need for postoperative bleb revisions, particularly in NVG, PCG, and TG subgroups, represents an important practical consideration. Given the small subgroup sizes and exploratory design, these findings warrant validation in larger, prospective studies.
- 1 August 2026
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 20, 1-17
Open AccessPreserflo MicroShunt Outcomes in Rare and Refractory Glaucoma Entities Compared with Matched Primary Open-Angle Glaucoma Controls: A Retrospective Exploratory Study
Purpose: To investigate the efficacy and safety of the Preserflo MicroShunt (PMS) in rare and refractory glaucoma entities (RRG) in comparison with primary open-angle glaucoma (POAG). Patients and Methods: In this retrospective exploratory study, the primary outcome was the complete 1-year success rate (≥ 20% reduction in IOP from baseline and ≤ 18 mmHg with no medication use). Kaplan–Meier estimates were compared between RRG and POAG (matched 1:1) using the log-rank test. Exploratory sub-analyses were performed for each RRG subgroup. The secondary outcomes included bleb revision and complication rates. Results: Eighty eyes were included in the RRG group (8 primary congenital (PCG), 11 juvenile open-angle (JOAG), 10 aphakic (AG), 14 combined mechanisms (CMG), 17 neovascular (NVG), 13 post-traumatic (TG), 4 oil-induced, 2 steroid-induced glaucoma, and 1 with idiopathically elevated episcleral venous pressure) and matched to 80 eyes with POAG based on baseline characteristics. The 1-year success rates were 56% in the RRG and 71% in the POAG groups (p = 0.0079). Exploratory subgroup analyses revealed significantly lower success in PCG (2/8), TG (8/13) and NVG (8/17). Success rates in the other groups were not significantly different from POAG. Bleb revisions were required significantly more frequently in the RRG group (58% vs 41%). Severe complications were observed in the RRG group, but did not reach significance. Conclusions: While the PMS demonstrated lower efficacy in RRG compared to POAG overall, this difference was primarily attributable to worse outcomes in NVG, TG, and PCG. Success rates in AG, JOAG, and CMG were not significantly different from POAG controls. The frequent need for postoperative bleb revisions, particularly in NVG, PCG, and TG subgroups, represents an important practical consideration. Given the small subgroup sizes and exploratory design, these findings warrant validation in larger, prospective studies.
- Open Access
- 1 November 2025
- Published by Wolters Kluwer Health in RETINAL Cases & Brief Reports
- Vol. 19 (6) , 793-798
A CASE OF ACUTE ZONAL OCCULT OUTER RETINOPATHY UNDER IMMUNOMODULATORY TREATMENT
Purpose: To describe the clinical course and treatment response of a case of acute zonal occult outer retinopathy. Methods: This is an observational case report. The examinations included ophthalmic examination, longitudinal multimodal imaging, visual field testing, electrophysiologic recordings, serologic analyses, and whole genome sequencing. Results: In this report, the authors present the case of an otherwise healthy 33-year-old woman with bilateral acute zonal occult outer retinopathy manifestation. Other possible causes of the observed retinal lesions were ruled out by extensive diagnostic workup. Treatment with oral prednisolone therapy led to temporal disease control but progression was observed after prednisolone discontinuation. A tapered oral prednisolone therapy in combination with adalimumab initiation prevented further progression for at least 21 months. Conclusion: Diagnosis of acute zonal occult outer retinopathy is frequently complicated by the unspecific symptoms of the disease and significant number of differential diagnoses. Complete diagnostic workup is important to rule out other etiologies. Owing to the lack of randomized controlled trials, therapeutic decisions obligatorily rely on empiric treatment decisions in combination with frequent follow-up examinations.
- 1 November 2025
- Published by Wolters Kluwer Health in RETINAL Cases & Brief Reports
- Vol. 19 (6) , 793-798
Open AccessA CASE OF ACUTE ZONAL OCCULT OUTER RETINOPATHY UNDER IMMUNOMODULATORY TREATMENT
Purpose: To describe the clinical course and treatment response of a case of acute zonal occult outer retinopathy. Methods: This is an observational case report. The examinations included ophthalmic examination, longitudinal multimodal imaging, visual field testing, electrophysiologic recordings, serologic analyses, and whole genome sequencing. Results: In this report, the authors present the case of an otherwise healthy 33-year-old woman with bilateral acute zonal occult outer retinopathy manifestation. Other possible causes of the observed retinal lesions were ruled out by extensive diagnostic workup. Treatment with oral prednisolone therapy led to temporal disease control but progression was observed after prednisolone discontinuation. A tapered oral prednisolone therapy in combination with adalimumab initiation prevented further progression for at least 21 months. Conclusion: Diagnosis of acute zonal occult outer retinopathy is frequently complicated by the unspecific symptoms of the disease and significant number of differential diagnoses. Complete diagnostic workup is important to rule out other etiologies. Owing to the lack of randomized controlled trials, therapeutic decisions obligatorily rely on empiric treatment decisions in combination with frequent follow-up examinations.
- Open Access
- 21 October 2025
- Published by Wiley in Acta Ophthalmologica
- Vol. 104 (3) , e239-e250
Incidence, risk factors, and outcomes of numerical hypotony and choroidal effusion following PRESERFLO MicroShunt implantation
Purpose: To evaluate the incidence, outcomes, and risk factors of numerical hypotony (NH) and choroidal effusion (CE) following standalone PRESERFLO MicroShunt (PMS) implantation. Methods: Primary open‐angle glaucoma (POAG) and pseudoexfoliative glaucoma (PXG) patients with uni‐ or bilateral surgery at a tertiary university hospital were retrospectively evaluated. Kaplan–Meier estimates of first‐operated eyes were used to analyse the cumulative incidence of NH (intraocular pressure [IOP] of <6 mmHg), CE, and CE requiring intervention. Risk factor analyses were performed using generalised linear mixed models on the patient level, including bilateral cases. Results: In total, 370 patients (235 POAG and 135 PXG) and 435 eyes (288 and 147) were included. The PXG group had a significantly higher incidence of NH (83.7% vs. 69.4%) and CE (34.6% vs. 20.6%). Interventions for CE were required significantly more in PXG patients (20.7% vs. 7.4%). The median CE duration was significantly longer in the PXG group (14 days vs. 7 days). The following risk factors were identified: PXG (development of NH, CE, and CE requiring intervention); spherical hyperopic refractive error (CE and CE requiring intervention); male sex and higher age (CE); number of preoperative medications (CE requiring intervention), lower preoperative IOP (NH), and higher postoperative IOP drop (CE). The 6‐month visual outcomes were not influenced by the hypotony criteria, but significantly more eyes treated for CE required subsequent bleb revisions. Conclusion: PXG and hyperopic eyes were at risk for developing postoperative CE requiring intervention. They should be monitored more closely and would benefit from primary intraluminal stenting.
- 21 October 2025
- Published by Wiley in Acta Ophthalmologica
- Vol. 104 (3) , e239-e250
Open AccessIncidence, risk factors, and outcomes of numerical hypotony and choroidal effusion following PRESERFLO MicroShunt implantation
Purpose: To evaluate the incidence, outcomes, and risk factors of numerical hypotony (NH) and choroidal effusion (CE) following standalone PRESERFLO MicroShunt (PMS) implantation. Methods: Primary open‐angle glaucoma (POAG) and pseudoexfoliative glaucoma (PXG) patients with uni‐ or bilateral surgery at a tertiary university hospital were retrospectively evaluated. Kaplan–Meier estimates of first‐operated eyes were used to analyse the cumulative incidence of NH (intraocular pressure [IOP] of <6 mmHg), CE, and CE requiring intervention. Risk factor analyses were performed using generalised linear mixed models on the patient level, including bilateral cases. Results: In total, 370 patients (235 POAG and 135 PXG) and 435 eyes (288 and 147) were included. The PXG group had a significantly higher incidence of NH (83.7% vs. 69.4%) and CE (34.6% vs. 20.6%). Interventions for CE were required significantly more in PXG patients (20.7% vs. 7.4%). The median CE duration was significantly longer in the PXG group (14 days vs. 7 days). The following risk factors were identified: PXG (development of NH, CE, and CE requiring intervention); spherical hyperopic refractive error (CE and CE requiring intervention); male sex and higher age (CE); number of preoperative medications (CE requiring intervention), lower preoperative IOP (NH), and higher postoperative IOP drop (CE). The 6‐month visual outcomes were not influenced by the hypotony criteria, but significantly more eyes treated for CE required subsequent bleb revisions. Conclusion: PXG and hyperopic eyes were at risk for developing postoperative CE requiring intervention. They should be monitored more closely and would benefit from primary intraluminal stenting.
- Open Access
- 6 December 2024
- Published by Taylor & Francis in Ocular Immunology and Inflammation
- p. 1-8
Preserflo MicroShunt Implantation for Glaucoma Secondary to Viral and Juvenile Idiopathic Arthritis-Related Anterior Uveitis
PurposeTo investigate the efficacy and safety of the Preserflo MicroShunt (PMS) in treating glaucoma secondary to different uveitic glaucoma (UG) types in a European population.MethodsThis study evaluated consecutive eyes with UG that received the PMS. The primary outcome measure was 12-month surgical success (>= 20% IOP reduction, target IOP of 6-21 mmHg). Complete success was considered without IOP-lowering medication or additional surgery other than needling. Qualified success A was considered regardless of medication use, and qualified success B regardless of medication and/or incisional bleb revision. The secondary outcome measures included revision and complication rates.ResultsTwenty-five eyes (viral group: 10 with Fuchs uveitis syndrome and six with herpetic uveitis; juvenile idiopathic arthritis (JIA) group: nine with JIA-related uveitis) were included. The 12-month complete success rate was significantly higher in the viral group than in the JIA group (69% vs 11%; p = 0.0059, log-rank test). The qualified success rates in the viral and JIA groups were 75% and 22% for category A (p = 0.029) and 94% and 56% for category B (p = 0.0237), respectively. Among the viral and JIA groups, 13% and 11% required medication, respectively. Incisional bleb revisions were conducted within 12 months in 25% and 78%, respectively (p = 0.0131, log-rank test). Complications were self-limiting, with no uveitic activity observed.ConclusionThe PMS is safe and effective for glaucoma secondary to viral anterior uveitis. Conversely, it is moderately effective in eyes with JIA-related UG, with a high probability of bleb fibrosis development.
- 6 December 2024
- Published by Taylor & Francis in Ocular Immunology and Inflammation
- p. 1-8
Open AccessPreserflo MicroShunt Implantation for Glaucoma Secondary to Viral and Juvenile Idiopathic Arthritis-Related Anterior Uveitis
PurposeTo investigate the efficacy and safety of the Preserflo MicroShunt (PMS) in treating glaucoma secondary to different uveitic glaucoma (UG) types in a European population.MethodsThis study evaluated consecutive eyes with UG that received the PMS. The primary outcome measure was 12-month surgical success (>= 20% IOP reduction, target IOP of 6-21 mmHg). Complete success was considered without IOP-lowering medication or additional surgery other than needling. Qualified success A was considered regardless of medication use, and qualified success B regardless of medication and/or incisional bleb revision. The secondary outcome measures included revision and complication rates.ResultsTwenty-five eyes (viral group: 10 with Fuchs uveitis syndrome and six with herpetic uveitis; juvenile idiopathic arthritis (JIA) group: nine with JIA-related uveitis) were included. The 12-month complete success rate was significantly higher in the viral group than in the JIA group (69% vs 11%; p = 0.0059, log-rank test). The qualified success rates in the viral and JIA groups were 75% and 22% for category A (p = 0.029) and 94% and 56% for category B (p = 0.0237), respectively. Among the viral and JIA groups, 13% and 11% required medication, respectively. Incisional bleb revisions were conducted within 12 months in 25% and 78%, respectively (p = 0.0131, log-rank test). Complications were self-limiting, with no uveitic activity observed.ConclusionThe PMS is safe and effective for glaucoma secondary to viral anterior uveitis. Conversely, it is moderately effective in eyes with JIA-related UG, with a high probability of bleb fibrosis development.
- Open Access
- 11 July 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (14) , 4066
Two-Year Results of XEN Gel Stent Implantation for Pseudoexfoliative Glaucoma in Phakic versus Pseudophakic Eyes
Objectives: To investigate whether phakia affects the outcome of XEN-45 gel stent implantation in the treatment of pseudoexfoliative glaucoma (PXG). Methods: A retrospective, comparative cohort study of 30 phakic and 55 pseudophakic PXG patients who received the XEN-45 gel stent at a tertiary centre. The primary outcome measure was two-year success defined as a ≥20% lowering of intraocular pressure (IOP) and a target IOP of 6–21 mmHg. Success was complete without and qualified irrespective of antiglaucoma medication use. Further glaucoma surgery other than needling was regarded as a failure. The secondary outcome measures included changes in IOP, revision and complication rates. Results: The complete two-year success rates were 70% and 59% in the phakic and pseudophakic groups, respectively (p = 0.75, log-rank test), and the qualified rates were 80% and 72%, respectively (p = 0.89). The median IOP reduction from baseline was 54% in phakic, and 46% in pseudophakic eyes. While needling rates were similar, the incidence of early incisional bleb revisions was significantly higher in the phakic eyes (13% vs. 0% within 3 months; p = 0.0098, chi-square). Increasing after a year, significantly more pseudophakic eyes failed due to secondary glaucoma surgery (16% vs. 0%; p = 0.0191). Conclusions: The XEN-45 gel stent offers equally effective IOP control for both phakic and pseudophakic patients. However, the onset of bleb revisions and the necessity for secondary glaucoma surgery differed significantly between the groups.
- 11 July 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (14) , 4066
Open AccessTwo-Year Results of XEN Gel Stent Implantation for Pseudoexfoliative Glaucoma in Phakic versus Pseudophakic Eyes
Objectives: To investigate whether phakia affects the outcome of XEN-45 gel stent implantation in the treatment of pseudoexfoliative glaucoma (PXG). Methods: A retrospective, comparative cohort study of 30 phakic and 55 pseudophakic PXG patients who received the XEN-45 gel stent at a tertiary centre. The primary outcome measure was two-year success defined as a ≥20% lowering of intraocular pressure (IOP) and a target IOP of 6–21 mmHg. Success was complete without and qualified irrespective of antiglaucoma medication use. Further glaucoma surgery other than needling was regarded as a failure. The secondary outcome measures included changes in IOP, revision and complication rates. Results: The complete two-year success rates were 70% and 59% in the phakic and pseudophakic groups, respectively (p = 0.75, log-rank test), and the qualified rates were 80% and 72%, respectively (p = 0.89). The median IOP reduction from baseline was 54% in phakic, and 46% in pseudophakic eyes. While needling rates were similar, the incidence of early incisional bleb revisions was significantly higher in the phakic eyes (13% vs. 0% within 3 months; p = 0.0098, chi-square). Increasing after a year, significantly more pseudophakic eyes failed due to secondary glaucoma surgery (16% vs. 0%; p = 0.0191). Conclusions: The XEN-45 gel stent offers equally effective IOP control for both phakic and pseudophakic patients. However, the onset of bleb revisions and the necessity for secondary glaucoma surgery differed significantly between the groups.
- Open Access
- 21 June 2024
- Published by Springer Nature in BMC Ophthalmology
- Vol. 24 (1) , 1-9
Long-term efficacy and safety of XEN-45 gel stent implantation in patients with normal-tension glaucoma
Background: Minimally invasive bleb surgery using the XEN-45 gel stent has not been established for the treatment of normal-tension glaucoma (NTG). The main objective of this study was to evaluate the long-term treatment efficacy and safety of XEN-45 in eyes with uncontrolled NTG. Methods: A retrospective analysis of patients with NTG who underwent XEN-45 gel stent implantation at university hospital Tuebingen between 2016 and 2021. The primary outcome measure was surgical success after three years defined as lowering of intraocular pressure (IOP) of ≥ 20%, with target IOP between 6 and 15 mmHg. Success was complete without and qualified irrespective of topical antiglaucoma medication use. The need for further glaucoma surgery, except for needling, was regarded as a failure. The secondary outcome measures included changes in mean IOP, number of antiglaucoma medications, and needling and complication rates. Results: Twenty-eight eyes from 23 patients were included in the final analysis. Complete and qualified success rates were 56.5% and 75% after three years, respectively. Mean postoperative IOP ± standard deviation decreased significantly after three years from 19.3 ± 2.0 mmHg at baseline to 13.7 ± 4.2 mmHg (n = 22; p < 0.0001). The median number of antiglaucoma medications decreased from 2 (range 0–4) to 0 after three years (range 0–3; p < 0.0001). Sixteen eyes (57%) required a median of 1 (range 1–3) needling procedures. One eye required further glaucoma surgery. No sight-threatening complications were observed. Conclusion: The XEN-45 stent is effective and safe for the long-term treatment of NTG. However, needling was frequently required to improve outcomes.
- 21 June 2024
- Published by Springer Nature in BMC Ophthalmology
- Vol. 24 (1) , 1-9
Open AccessLong-term efficacy and safety of XEN-45 gel stent implantation in patients with normal-tension glaucoma
Background: Minimally invasive bleb surgery using the XEN-45 gel stent has not been established for the treatment of normal-tension glaucoma (NTG). The main objective of this study was to evaluate the long-term treatment efficacy and safety of XEN-45 in eyes with uncontrolled NTG. Methods: A retrospective analysis of patients with NTG who underwent XEN-45 gel stent implantation at university hospital Tuebingen between 2016 and 2021. The primary outcome measure was surgical success after three years defined as lowering of intraocular pressure (IOP) of ≥ 20%, with target IOP between 6 and 15 mmHg. Success was complete without and qualified irrespective of topical antiglaucoma medication use. The need for further glaucoma surgery, except for needling, was regarded as a failure. The secondary outcome measures included changes in mean IOP, number of antiglaucoma medications, and needling and complication rates. Results: Twenty-eight eyes from 23 patients were included in the final analysis. Complete and qualified success rates were 56.5% and 75% after three years, respectively. Mean postoperative IOP ± standard deviation decreased significantly after three years from 19.3 ± 2.0 mmHg at baseline to 13.7 ± 4.2 mmHg (n = 22; p < 0.0001). The median number of antiglaucoma medications decreased from 2 (range 0–4) to 0 after three years (range 0–3; p < 0.0001). Sixteen eyes (57%) required a median of 1 (range 1–3) needling procedures. One eye required further glaucoma surgery. No sight-threatening complications were observed. Conclusion: The XEN-45 stent is effective and safe for the long-term treatment of NTG. However, needling was frequently required to improve outcomes.
- Open Access
- 1 August 2023
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 17, 2243-2249
New XEN63 Gel Stent Implantation in Open-Angle Glaucoma: A Two-Year Follow-Up Pilot Study
Purpose: The XEN gel stent was developed to reduce the risks of filtration surgery by standardizing the outflow of aqueous humor into the subconjunctival space. Recently, a modified version of the XEN63 gel stent was introduced. The goal of this study was to assess its efficacy and safety. Methods: This is a prospective, nonrandomized, observational, consecutive case series study at a single tertiary centre. Patients with open-angle glaucoma with above target intraocular pressure (IOP) despite maximal tolerated medication were included. The primary outcome was a change of median IOP. Secondary outcomes included a change in the number of medications, complete success, needling and complication rates. Success was defined as a lowering of IOP > 20% from baseline and IOP ≤ 14 mmHg. Complete success indicated that the target IOP was reached without medications. Results: Six patients were included. The median IOP decreased from 35.5 mmHg (25.0– 40.0 mmHg) at baseline to 11.5 mmHg (4.0– 15.0 mmHg, p = 0.03), and median IOP-lowering medication was reduced from 4.0 (3.0– 4.0) at baseline to 0 (0– 1.0, p = 0.03) after two years. Five patients (83.0%) had a complete success after two years. Two patients (33.0%) required a needling procedure. Three patients (50.0%) required an intervention due to symptomatic hypotony within the first three weeks postoperatively. Hypotony resolved completely or was asymptomatic after three months. Conclusion: Our study demonstrated a statistically significant reduction in both IOP and number of IOP-lowering medications. Complications were well manageable and had no long-term sequelae.
- 1 August 2023
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 17, 2243-2249
Open AccessNew XEN63 Gel Stent Implantation in Open-Angle Glaucoma: A Two-Year Follow-Up Pilot Study
Purpose: The XEN gel stent was developed to reduce the risks of filtration surgery by standardizing the outflow of aqueous humor into the subconjunctival space. Recently, a modified version of the XEN63 gel stent was introduced. The goal of this study was to assess its efficacy and safety. Methods: This is a prospective, nonrandomized, observational, consecutive case series study at a single tertiary centre. Patients with open-angle glaucoma with above target intraocular pressure (IOP) despite maximal tolerated medication were included. The primary outcome was a change of median IOP. Secondary outcomes included a change in the number of medications, complete success, needling and complication rates. Success was defined as a lowering of IOP > 20% from baseline and IOP ≤ 14 mmHg. Complete success indicated that the target IOP was reached without medications. Results: Six patients were included. The median IOP decreased from 35.5 mmHg (25.0– 40.0 mmHg) at baseline to 11.5 mmHg (4.0– 15.0 mmHg, p = 0.03), and median IOP-lowering medication was reduced from 4.0 (3.0– 4.0) at baseline to 0 (0– 1.0, p = 0.03) after two years. Five patients (83.0%) had a complete success after two years. Two patients (33.0%) required a needling procedure. Three patients (50.0%) required an intervention due to symptomatic hypotony within the first three weeks postoperatively. Hypotony resolved completely or was asymptomatic after three months. Conclusion: Our study demonstrated a statistically significant reduction in both IOP and number of IOP-lowering medications. Complications were well manageable and had no long-term sequelae.